Study on the Weight Loss Effects and Mechanisms of Probiotic Preparation Intervention in Weight Cyclers

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorPeking Union Medical College Hospital

About this trial

1. Study Background and Purpose Obesity is a complex chronic disease closely linked to comorbidities such as cardiovascular disease, hypertension, and diabetes. With lifestyle changes, obesity prevalence continues to rise. Current treatments focus on weight loss through dietary control and exercise, but weight regain is common due to metabolic adaptations (e.g., post-caloric restriction). Gut microbiota play a critical role in weight management, and probiotics may reduce weight regain by modulating appetite and metabolism. Studies suggest probiotics enhance satiety and reduce appetite. This study aims to evaluate the potential of probiotics in obesity management, specifically their impact on gut microbiota modulation and hormonal regulation to mitigate weight regain. Ethical approval has been obtained from the Peking Union Medical College Hospital Ethics Committee. 2. Study Design

This 198-participant, randomized, interventional trial will assign subjects to three groups (1:1:1 ratio):

Placebo group (maltodextrin-based placebo) Probiotic Group 1 Probiotic Group 2 Randomization will be conducted via sealed envelopes (no researcher/participant bias). All groups receive standardized nutritional counseling, caloric restriction plans, and body composition assessments. Probiotics (produced by Shenzhen BaoShiJian Biotechnology Co., Ltd., compliant with standard Q/BSJ 0023S-2024) will be administered orally (2 bottles twice daily) for 84 days . 3. Study Procedure Informed Consent : Required before participation. Screening Phase : Demographic history, medical records, concomitant medications, validated questionnaires, body composition analysis, and blood/urine/stool tests.

Intervention : Daily probiotic or placebo intake for 84 days. Follow-ups : Visits at Day 42 and Day 85 for adherence checks, anthropometric measurements, and repeat testing. 4. Study Completion Duration : 84 days. Post-Study : Placebo group receives 1-month free probiotic supply; others return to standard care. A 30-day post-study follow-up (phone/WeChat) will assess safety.

Withdrawal : Participants may exit anytime. Investigators may withdraw participants for safety reasons. 5. Potential Benefits Personalized nutrition counseling and body composition reports. Free clinical evaluations and health coaching. Contribution to novel weight management strategies for weight-cycling populations. 6. Risks and Discomforts Adverse Events : Gastrointestinal symptoms or discomfort. Immediate reporting required for medical management.

Inconveniences :

3 on-site visits (blood/urine/stool tests, anthropometry) with fasting blood draws (\~7-20 mL/session).

1 telehealth visit (25 min questionnaire). Daily diary cards. Compensation : 150 RMB travel reimbursement + study-provided scales. 7. Alternative Options

Participants may opt for:

Intermittent fasting. Pharmacotherapy (e.g., GLP-1 agonists). Standard dietary recommendations. 8. New Information Any significant findings during the trial will be communicated to participants, who may choose to continue or withdraw.

9\. Costs and Reimbursement No-cost : All investigational products (probiotics/placebo), lab tests, and body composition analyses.

Reimbursement : 150 RMB travel compensation + study tools (body fat scale, food scale, tape measure).

10\. Adverse Event Policy All injuries attributed to the intervention will be covered by Shenzhen BaoShiJian Biotechnology Co., Ltd. 's insurance. Legal liability extends beyond insurance coverage.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Obesity : BMI ≥28 kg/m² and <35 kg/m².

Age : 18-60 years (inclusive), male or female.

Comprehension and Voluntariness : Ability to understand the weight loss protocol and willingness to complete the full study.

Informed Consent : Signed informed consent form.

Disqualifiers

Weight-Loss Medications : Current use of medications affecting weight (e.g., orlistat, GLP-1 receptor agonists, metformin).

Diabetes Mellitus : Diagnosed diabetes or use of antidiabetic medications.

Pregnancy/Lactation : Currently pregnant, breastfeeding, or planning pregnancy within 3 months.

Severe Organ Dysfunction : Advanced cardiovascular, hepatic, pulmonary, renal, or other critical organic diseases.

Trial design

Design model

Parallel

Treatments tested in this trial

  • WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100).

    Dietary supplement

    Product : WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100). Ingredients : Stachyose, fructooligosaccharides, isomaltooligosaccharides, maltodextrin, Lactiplantibacillus plantarum CECT7527, Lactiplantibacillus plantarum CECT7528, Lactiplantibacillus plantarum CECT7529, Lactobacillus acidophilus GOLDGUT-LA100, and Epigallocatechin gallate (EGCG). Administration : Twice daily (2 bottles per dose) after meals for 12 weeks.

  • WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100) + WONDERLAB Weight Management Probiotic Food.

    Dietary supplement

    Product : WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100) + WONDERLAB Weight Management Probiotic Food. Ingredients : S100 Components : As above. Weight Management Components : Isomaltooligosaccharides, fructooligosaccharides, maltodextrin, Lactobacillus fermentum K7-Lb1, Lactobacillus fermentum K8-Lb1, Lactobacillus fermentum K11-Lb3, Euglena gracilis, and phosphatidylserine. Administration : Twice daily (2 bottles per dose) after meals for 12 weeks.

  • Placebo

    Dietary supplement

    Daily oral administration of maltodextrin-based placebo (identical in taste, appearance, and packaging to probiotic products) twice daily (2 bottles per dose) for 12 weeks.

Treatment groups

198 Participants
are divided into 3 treatment groups
Group A: Probiotic Group 1Experimental treatment 1 intervention
Group B: Probiotic Group 2Experimental treatment 1 intervention
Group C: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Percentage of Participants with >5% Body Weight Loss

Proportion of participants achieving ≥5% reduction in body weight from baseline (D0) to end of intervention (D85).

Time frame
From baseline (D0) to end of intervention (D85 ±7 days)

Secondary outcomes

1

Change in Power of Food Scale (PFS) Score

The PFS assesses hedonic hunger on a 15-75 scale. Higher scores indicate greater responsiveness to the food environment.

Time frame
From baseline (D0) to end of intervention (D85 ±7 days)
2

Change in Fasting Insulin Concentration

Measured in fasting state using immunoassay.Unit of Measure: μU/mL

Time frame
From baseline (D0) to end of intervention (D85 ±7 days)
3

Change in Body Weight

Measured in kilograms using a calibrated digital scale.

Time frame
From baseline (D0) to end of intervention (D85 ±7 days)
4

Change in Triglyceride Concentration

Fasting triglycerides measured via enzymatic assay.Unit of Measure: mmol/L

Time frame
From baseline (D0) to end of intervention (D85 ±7 days)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: